Which has higher earnings & valuation, ZVRA or NBP?

Zevra Therapeutics has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zevra Therapeutics $106.47M 7.25 $83.23M $1.99 6.56 I-Mab $3.89M 53.51 -$46.27M -$0.36 N/A

Which has stronger earnings and valuation, RGNX or NBP?

I-Mab has lower revenue, but higher earnings than REGENXBIO. I-Mab is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio REGENXBIO $170.44M 3.73 -$193.88M -$5.60 N/A I-Mab $3.89M 53.51 -$46.27M -$0.36 N/A

Is RGNX or NBP more profitable?

I-Mab has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. I-Mab's return on equity of 0.00% beat REGENXBIO's return on equity. Company Net Margins Return on Equity Return on Assets REGENXBIO -330.23% -232.50% -61.02% I-Mab N/A N/A N/A

I-Mab (NBP) Competitors

$1.80 -0.06 (-3.23%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$1.91 +0.11 (+6.33%)

As of 05:13 AM Eastern

Compare

NBP vs. AMPH, ZVRA, ESPR, RGNX, and ACRS

Should you buy I-Mab stock or one of its competitors? MarketBeat compares I-Mab with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with I-Mab include Amphastar Pharmaceuticals (AMPH), Zevra Therapeutics (ZVRA), Esperion Therapeutics (ESPR), REGENXBIO (RGNX), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry.

How does I-Mab compare to Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and I-Mab (NASDAQ:NBP) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 38.4% of I-Mab shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by company insiders. Comparatively, 22.1% of I-Mab shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Amphastar Pharmaceuticals presently has a consensus target price of $22.00, suggesting a potential upside of 16.96%. I-Mab has a consensus target price of $9.00, suggesting a potential upside of 400.00%. Given I-Mab's stronger consensus rating and higher possible upside, analysts clearly believe I-Mab is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	3 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.63
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Amphastar Pharmaceuticals has a net margin of 11.00% compared to I-Mab's net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat I-Mab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
I-Mab	N/A	N/A	N/A

Amphastar Pharmaceuticals has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, I-Mab has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

In the previous week, Amphastar Pharmaceuticals had 3 more articles in the media than I-Mab. MarketBeat recorded 4 mentions for Amphastar Pharmaceuticals and 1 mentions for I-Mab. I-Mab's average media sentiment score of 0.43 beat Amphastar Pharmaceuticals' score of 0.36 indicating that I-Mab is being referred to more favorably in the news media.

Company	Overall Sentiment
Amphastar Pharmaceuticals	Neutral
I-Mab	Neutral

Amphastar Pharmaceuticals has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.15	$98.09M	$1.66	11.33
I-Mab	$3.89M	53.51	-$46.27M	-$0.36	N/A

Summary

Amphastar Pharmaceuticals beats I-Mab on 10 of the 16 factors compared between the two stocks.

How does I-Mab compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and I-Mab (NASDAQ:NBP) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

In the previous week, Zevra Therapeutics had 3 more articles in the media than I-Mab. MarketBeat recorded 4 mentions for Zevra Therapeutics and 1 mentions for I-Mab. Zevra Therapeutics' average media sentiment score of 0.89 beat I-Mab's score of 0.43 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Zevra Therapeutics	Positive
I-Mab	Neutral

Zevra Therapeutics has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	7.25	$83.23M	$1.99	6.56
I-Mab	$3.89M	53.51	-$46.27M	-$0.36	N/A

Zevra Therapeutics currently has a consensus price target of $29.29, suggesting a potential upside of 124.24%. I-Mab has a consensus price target of $9.00, suggesting a potential upside of 400.00%. Given I-Mab's higher probable upside, analysts plainly believe I-Mab is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Zevra Therapeutics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, I-Mab has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 38.4% of I-Mab shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 22.1% of I-Mab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Zevra Therapeutics has a net margin of 101.58% compared to I-Mab's net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat I-Mab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
I-Mab	N/A	N/A	N/A

Summary

Zevra Therapeutics beats I-Mab on 11 of the 16 factors compared between the two stocks.

How does I-Mab compare to Esperion Therapeutics?

Esperion Therapeutics (NASDAQ:ESPR) and I-Mab (NASDAQ:NBP) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Esperion Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, I-Mab has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

Esperion Therapeutics presently has a consensus target price of $5.54, suggesting a potential upside of 74.21%. I-Mab has a consensus target price of $9.00, suggesting a potential upside of 400.00%. Given I-Mab's higher probable upside, analysts clearly believe I-Mab is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

47.4% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 38.4% of I-Mab shares are held by institutional investors. 1.6% of Esperion Therapeutics shares are held by insiders. Comparatively, 22.1% of I-Mab shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Esperion Therapeutics has a net margin of 0.12% compared to I-Mab's net margin of 0.00%. I-Mab's return on equity of 0.00% beat Esperion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
I-Mab	N/A	N/A	N/A

In the previous week, Esperion Therapeutics had 5 more articles in the media than I-Mab. MarketBeat recorded 6 mentions for Esperion Therapeutics and 1 mentions for I-Mab. Esperion Therapeutics' average media sentiment score of 1.22 beat I-Mab's score of 0.43 indicating that Esperion Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Esperion Therapeutics	Positive
I-Mab	Neutral

Esperion Therapeutics has higher revenue and earnings than I-Mab. Esperion Therapeutics is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A
I-Mab	$3.89M	53.51	-$46.27M	-$0.36	N/A

Summary

Esperion Therapeutics beats I-Mab on 8 of the 14 factors compared between the two stocks.

How does I-Mab compare to REGENXBIO?

REGENXBIO (NASDAQ:RGNX) and I-Mab (NASDAQ:NBP) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

REGENXBIO currently has a consensus price target of $23.82, suggesting a potential upside of 93.80%. I-Mab has a consensus price target of $9.00, suggesting a potential upside of 400.00%. Given I-Mab's higher possible upside, analysts plainly believe I-Mab is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, REGENXBIO had 5 more articles in the media than I-Mab. MarketBeat recorded 6 mentions for REGENXBIO and 1 mentions for I-Mab. REGENXBIO's average media sentiment score of 0.87 beat I-Mab's score of 0.43 indicating that REGENXBIO is being referred to more favorably in the media.

Company	Overall Sentiment
REGENXBIO	Positive
I-Mab	Neutral

REGENXBIO has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, I-Mab has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

I-Mab has lower revenue, but higher earnings than REGENXBIO. I-Mab is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	3.73	-$193.88M	-$5.60	N/A
I-Mab	$3.89M	53.51	-$46.27M	-$0.36	N/A

I-Mab has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. I-Mab's return on equity of 0.00% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-330.23%	-232.50%	-61.02%
I-Mab	N/A	N/A	N/A

88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 14.2% of REGENXBIO shares are owned by company insiders. Comparatively, 22.1% of I-Mab shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

I-Mab beats REGENXBIO on 9 of the 16 factors compared between the two stocks.

How does I-Mab compare to Aclaris Therapeutics?

I-Mab (NASDAQ:NBP) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

I-Mab has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

I-Mab has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. I-Mab's return on equity of 0.00% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

I-Mab has higher earnings, but lower revenue than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	53.51	-$46.27M	-$0.36	N/A
Aclaris Therapeutics	$7.83M	96.85	-$64.92M	-$0.56	N/A

I-Mab presently has a consensus price target of $9.00, indicating a potential upside of 400.00%. Aclaris Therapeutics has a consensus price target of $11.50, indicating a potential upside of 111.79%. Given I-Mab's higher probable upside, research analysts plainly believe I-Mab is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

In the previous week, Aclaris Therapeutics had 1 more articles in the media than I-Mab. MarketBeat recorded 2 mentions for Aclaris Therapeutics and 1 mentions for I-Mab. Aclaris Therapeutics' average media sentiment score of 1.89 beat I-Mab's score of 0.43 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
I-Mab	Neutral
Aclaris Therapeutics	Very Positive

38.4% of I-Mab shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

I-Mab beats Aclaris Therapeutics on 9 of the 17 factors compared between the two stocks.

Get I-Mab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBP vs. The Competition

Export

Metric	I-Mab	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$215.11M	$3.12B	$4.39B	$12.44B
Dividend Yield	N/A	15.23%	30.61%	8.42%
P/E Ratio	-5.00	13.27	23.66	24.38
Price / Sales	53.51	2,764.91	147.54	91.92
Price / Cash	N/A	25.74	165.47	59.36
Price / Book	0.90	8.81	12.86	6.33
Net Income	-$46.27M	-$34.05M	$118.20M	$331.02M
7 Day Performance	-6.74%	0.58%	-0.83%	-0.33%
1 Month Performance	22.45%	-0.95%	-2.89%	-1.29%
1 Year Performance	N/A	14.80%	11.37%	21.30%

I-Mab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBP I-Mab	3.5289 of 5 stars	$1.80 -3.2%	$9.00 +400.0%	N/A	$215.11M	$3.89M	N/A	380
AMPH Amphastar Pharmaceuticals	3.2928 of 5 stars	$18.72 -1.6%	$22.00 +17.5%	-14.3%	$838.65M	$719.89M	11.28	1,976	Gap Up
ZVRA Zevra Therapeutics	4.35 of 5 stars	$13.35 -4.2%	$29.29 +119.4%	+2.1%	$824.06M	$106.47M	6.71	20	Analyst Upgrade
ESPR Esperion Therapeutics	3.4037 of 5 stars	$3.18 -0.3%	$5.54 +74.2%	N/A	$822.04M	$403.14M	N/A	200	Positive News High Trading Volume
RGNX REGENXBIO	3.4469 of 5 stars	$13.95 -10.9%	$23.82 +70.7%	+41.3%	$809.07M	$170.44M	N/A	370

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBP) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

I-Mab (NBP) Competitors

NBP vs. AMPH, ZVRA, ESPR, RGNX, and ACRS

How does I-Mab compare to Amphastar Pharmaceuticals?

Summary

How does I-Mab compare to Zevra Therapeutics?

Summary

How does I-Mab compare to Esperion Therapeutics?

Summary

How does I-Mab compare to REGENXBIO?

Summary

How does I-Mab compare to Aclaris Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP vs. The Competition

I-Mab Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

I-Mab (NBP) Competitors

NBP vs. AMPH, ZVRA, ESPR, RGNX, and ACRS

How does I-Mab compare to Amphastar Pharmaceuticals?

Do institutionals and insiders have more ownership in AMPH or NBP?

Do analysts rate AMPH or NBP?

Is AMPH or NBP more profitable?

Which has more risk and volatility, AMPH or NBP?

Does the media refer more to AMPH or NBP?

Which has better valuation and earnings, AMPH or NBP?

Summary

How does I-Mab compare to Zevra Therapeutics?

Does the media refer more to ZVRA or NBP?

Which has higher earnings & valuation, ZVRA or NBP?

Do analysts rate ZVRA or NBP?

Which has more risk & volatility, ZVRA or NBP?

Do insiders and institutionals have more ownership in ZVRA or NBP?

Is ZVRA or NBP more profitable?

Summary

How does I-Mab compare to Esperion Therapeutics?

Which has more volatility & risk, ESPR or NBP?

Do analysts recommend ESPR or NBP?

Do insiders & institutionals have more ownership in ESPR or NBP?

Is ESPR or NBP more profitable?

Does the media refer more to ESPR or NBP?

Which has preferable valuation & earnings, ESPR or NBP?

Summary

How does I-Mab compare to REGENXBIO?

Do analysts recommend RGNX or NBP?

Does the media refer more to RGNX or NBP?

Which has more volatility and risk, RGNX or NBP?

Which has stronger earnings and valuation, RGNX or NBP?

Is RGNX or NBP more profitable?

Do institutionals and insiders have more ownership in RGNX or NBP?

Summary

How does I-Mab compare to Aclaris Therapeutics?

Which has more volatility & risk, NBP or ACRS?

Is NBP or ACRS more profitable?

Which has stronger earnings & valuation, NBP or ACRS?

Do analysts prefer NBP or ACRS?

Does the media prefer NBP or ACRS?

Do institutionals and insiders have more ownership in NBP or ACRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP vs. The Competition

I-Mab Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools